Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes.

Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, Castaño-Díez D, Schweighauser G, Graff-Meyer A, Goldie KN, Sütterlin R, Huisman E, Ingrassia A, Gier Y, Rozemuller AJM, Wang J, Paepe A, Erny J, Staempfli A, Hoernschemeyer J, Großerüschkamp F, Niedieker D, El-Mashtoly SF, Quadri M, Van IJcken WFJ, Bonifati V, Gerwert K, Bohrmann B, Frank S, Britschgi M, Stahlberg H, Van de Berg WDJ, Lauer ME.

Nat Neurosci. 2019 Jul;22(7):1099-1109. doi: 10.1038/s41593-019-0423-2. Epub 2019 Jun 24.

PMID:
31235907
2.

Cerebral Corpora amylacea are dense membranous labyrinths containing structurally preserved cell organelles.

Navarro PP, Genoud C, Castaño-Díez D, Graff-Meyer A, Lewis AJ, de Gier Y, Lauer ME, Britschgi M, Bohrmann B, Frank S, Hench J, Schweighauser G, Rozemuller AJM, van de Berg WDJ, Stahlberg H, Shahmoradian SH.

Sci Rep. 2018 Dec 21;8(1):18046. doi: 10.1038/s41598-018-36223-4.

3.

Human stem cell-derived monocytes and microglia-like cells reveal impaired amyloid plaque clearance upon heterozygous or homozygous loss of TREM2.

Claes C, Van Den Daele J, Boon R, Schouteden S, Colombo A, Monasor LS, Fiers M, Ordovás L, Nami F, Bohrmann B, Tahirovic S, De Strooper B, Verfaillie CM.

Alzheimers Dement. 2019 Mar;15(3):453-464. doi: 10.1016/j.jalz.2018.09.006. Epub 2018 Nov 12.

4.

Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.

Brendel M, Jaworska A, Overhoff F, Blume T, Probst F, Gildehaus FJ, Bartenstein P, Haass C, Bohrmann B, Herms J, Willem M, Rominger A.

Theranostics. 2018 Sep 9;8(18):4957-4968. doi: 10.7150/thno.27868. eCollection 2018.

5.

Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode.

Weber F, Bohrmann B, Niewoehner J, Fischer JAA, Rueger P, Tiefenthaler G, Moelleken J, Bujotzek A, Brady K, Singer T, Ebeling M, Iglesias A, Freskgård PO.

Cell Rep. 2018 Jan 2;22(1):149-162. doi: 10.1016/j.celrep.2017.12.019.

6.

HtrA1 Mediated Intracellular Effects on Tubulin Using a Polarized RPE Disease Model.

Melo E, Oertle P, Trepp C, Meistermann H, Burgoyne T, Sborgi L, Cabrera AC, Chen CY, Hoflack JC, Kam-Thong T, Schmucki R, Badi L, Flint N, Ghiani ZE, Delobel F, Stucki C, Gromo G, Einhaus A, Hornsperger B, Golling S, Siebourg-Polster J, Gerber F, Bohrmann B, Futter C, Dunkley T, Hiller S, Schilling O, Enzmann V, Fauser S, Plodinec M, Iacone R.

EBioMedicine. 2018 Jan;27:258-274. doi: 10.1016/j.ebiom.2017.12.011. Epub 2017 Dec 13.

7.

Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice.

Barrow P, Villabruna L, Hoberman A, Bohrmann B, Richter WF, Schubert C.

Reprod Toxicol. 2017 Oct;73:362-371. doi: 10.1016/j.reprotox.2017.07.014. Epub 2017 Jul 25.

PMID:
28754630
8.

Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.

Borroni E, Bohrmann B, Grueninger F, Prinssen E, Nave S, Loetscher H, Chinta SJ, Rajagopalan S, Rane A, Siddiqui A, Ellenbroek B, Messer J, Pähler A, Andersen JK, Wyler R, Cesura AM.

J Pharmacol Exp Ther. 2017 Sep;362(3):413-423. doi: 10.1124/jpet.117.241653. Epub 2017 Jun 22.

PMID:
28642233
9.

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance.

Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C.

EMBO Mol Med. 2016 Sep 1;8(9):992-1004. doi: 10.15252/emmm.201606370. Print 2016 Sep.

10.

A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies.

Lathuilière A, Laversenne V, Astolfo A, Kopetzki E, Jacobsen H, Stampanoni M, Bohrmann B, Schneider BL, Aebischer P.

Brain. 2016 May;139(Pt 5):1587-604. doi: 10.1093/brain/aww036. Epub 2016 Mar 8.

PMID:
26956423
11.

Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.

Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilpert H, Jacobsen B, Terwel D, Tanghe A, Bohrmann B.

J Neurosci. 2014 Aug 27;34(35):11621-30. doi: 10.1523/JNEUROSCI.1405-14.2014.

12.

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.

Collin L, Bohrmann B, Göpfert U, Oroszlan-Szovik K, Ozmen L, Grüninger F.

Brain. 2014 Oct;137(Pt 10):2834-46. doi: 10.1093/brain/awu213. Epub 2014 Jul 31.

PMID:
25085375
13.

Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.

Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, Loetscher H, Ghosh A, Freskgård PO.

Neuron. 2014 Jan 8;81(1):49-60. doi: 10.1016/j.neuron.2013.10.061.

14.

Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation.

Lathuilière A, Bohrmann B, Kopetzki E, Schweitzer C, Jacobsen H, Moniatte M, Aebischer P, Schneider BL.

Biomaterials. 2014 Jan;35(2):792-802.

PMID:
24344356
15.

Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.

Ullmer C, Zoffmann S, Bohrmann B, Matile H, Lindemann L, Flor P, Malherbe P.

Br J Pharmacol. 2012 Dec;167(7):1448-66. doi: 10.1111/j.1476-5381.2012.02090.x.

16.

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L.

Arch Neurol. 2012 Feb;69(2):198-207. doi: 10.1001/archneurol.2011.1538. Epub 2011 Oct 10.

PMID:
21987394
17.

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β.

Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H.

J Alzheimers Dis. 2012;28(1):49-69. doi: 10.3233/JAD-2011-110977.

PMID:
21955818
18.

Novel screening cascade identifies MKK4 as key kinase regulating Tau phosphorylation at Ser422.

Grueninger F, Bohrmann B, Christensen K, Graf M, Roth D, Czech C.

Mol Cell Biochem. 2011 Nov;357(1-2):199-207. doi: 10.1007/s11010-011-0890-6. Epub 2011 Jun 3.

PMID:
21638028
19.

Altered distribution of mGlu2 receptors in β-amyloid-affected brain regions of Alzheimer cases and aged PS2APP mice.

Richards G, Messer J, Faull RL, Stadler H, Wichmann J, Huguenin P, Bohrmann B, Mutel V.

Brain Res. 2010 Dec 2;1363:180-90. doi: 10.1016/j.brainres.2010.09.072. Epub 2010 Sep 25.

PMID:
20875805
20.

Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice.

Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR, Weidensteiner C, von Kienlin M, Ozmen L.

Neurobiol Dis. 2010 Feb;37(2):294-306. doi: 10.1016/j.nbd.2009.09.004. Epub 2009 Sep 23.

PMID:
19781645
21.

Cortical hypoperfusion in the B6.PS2APP mouse model for Alzheimer's disease: comprehensive phenotyping of vascular and tissular parameters by MRI.

Weidensteiner C, Metzger F, Bruns A, Bohrmann B, Kuennecke B, von Kienlin M.

Magn Reson Med. 2009 Jul;62(1):35-45. doi: 10.1002/mrm.21985.

22.

Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice.

Nordquist RE, Savignac H, Pauly-Evers M, Walker G, Knoflach F, Borroni E, Glaentzlin P, Bohrmann B, Messer J, Ozmen L, Albientz A, Spooren W.

Behav Pharmacol. 2008 Sep;19(5-6):518-29. doi: 10.1097/FBP.0b013e32830cd7f5.

PMID:
18690106
23.

Antiproliferative activity of the human IFN-alpha-inducible protein IFI44.

Hallen LC, Burki Y, Ebeling M, Broger C, Siegrist F, Oroszlan-Szovik K, Bohrmann B, Certa U, Foser S.

J Interferon Cytokine Res. 2007 Aug;27(8):675-80.

PMID:
17784819
24.

Thermodynamic studies on the interaction of antibodies with beta-amyloid peptide.

Brockhaus M, Ganz P, Huber W, Bohrmann B, Loetscher HR, Seelig J.

J Phys Chem B. 2007 Feb 8;111(5):1238-43.

PMID:
17266280
25.

High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.

Güntert A, Döbeli H, Bohrmann B.

Neuroscience. 2006 Dec 1;143(2):461-75. Epub 2006 Sep 27.

PMID:
17008022
26.

Acute renal effects of intravenous bisphosphonates in the rat.

Pfister T, Atzpodien E, Bohrmann B, Bauss F.

Basic Clin Pharmacol Toxicol. 2005 Dec;97(6):374-81.

27.

3D structure of Alzheimer's amyloid-beta(1-42) fibrils.

Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, Schubert D, Riek R.

Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17342-7. Epub 2005 Nov 17.

28.

Quantification of the A beta peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry.

Rüfenacht P, Güntert A, Bohrmann B, Ducret A, Döbeli H.

J Mass Spectrom. 2005 Feb;40(2):193-201.

PMID:
15706631
29.

Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis--novel targets for pharmacotherapy in atherosclerosis.

Ihling C, Bohrmann B, Schaefer HE, Technau-Ihling K, Loeffler BM.

Curr Vasc Pharmacol. 2004 Jul;2(3):249-58. Review.

PMID:
15320823
30.

Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease.

Kalback W, Esh C, Castaño EM, Rahman A, Kokjohn T, Luehrs DC, Sue L, Cisneros R, Gerber F, Richardson C, Bohrmann B, Walker DG, Beach TG, Roher AE.

Neurol Res. 2004 Jul;26(5):525-39. Review.

PMID:
15265270
31.

PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation.

Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA.

J Neurosci. 2003 Oct 1;23(26):8989-9003.

32.

The N'-terminal domain of glyceraldehyde-3-phosphate dehydrogenase of the apicomplexan Plasmodium falciparum mediates GTPase Rab2-dependent recruitment to membranes.

Daubenberger CA, Tisdale EJ, Curcic M, Diaz D, Silvie O, Mazier D, Eling W, Bohrmann B, Matile H, Pluschke G.

Biol Chem. 2003 Aug;384(8):1227-37.

PMID:
12974391
33.

Inhibition of proliferation by 1-8U in interferon-alpha-responsive and non-responsive cell lines.

Brem R, Oraszlan-Szovik K, Foser S, Bohrmann B, Certa U.

Cell Mol Life Sci. 2003 Jun;60(6):1235-48.

PMID:
12861389
34.

Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis.

Ihling C, Szombathy T, Bohrmann B, Brockhaus M, Schaefer HE, Loeffler BM.

Circulation. 2001 Aug 21;104(8):864-9.

PMID:
11514370
35.

Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates.

Bohrmann B, Adrian M, Dubochet J, Kuner P, Müller F, Huber W, Nordstedt C, Döbeli H.

J Struct Biol. 2000 Jun;130(2-3):232-46.

PMID:
10940228
36.
37.

Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor.

Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y.

Blood. 2000 Jul 1;96(1):170-5.

38.

Controlling polymerization of beta-amyloid and prion-derived peptides with synthetic small molecule ligands.

Kuner P, Bohrmann B, Tjernberg LO, Näslund J, Huber G, Celenk S, Grüninger-Leitch F, Richards JG, Jakob-Roetne R, Kemp JA, Nordstedt C.

J Biol Chem. 2000 Jan 21;275(3):1673-8.

39.

Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues.

Bohrmann B, Tjernberg L, Kuner P, Poli S, Levet-Trafit B, Näslund J, Richards G, Huber W, Döbeli H, Nordstedt C.

J Biol Chem. 1999 Jun 4;274(23):15990-5.

40.

Blood-borne tissue factor: another view of thrombosis.

Giesen PL, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y.

Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2311-5.

41.

Integrin alphaIIb beta3 reconstituted into lipid bilayers is nonclustered in its activated state but clusters after fibrinogen binding.

Erb EM, Tangemann K, Bohrmann B, Müller B, Engel J.

Biochemistry. 1997 Jun 17;36(24):7395-402.

PMID:
9200686
42.

The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology.

Seilheimer B, Bohrmann B, Bondolfi L, Müller F, Stüber D, Döbeli H.

J Struct Biol. 1997 Jun;119(1):59-71.

PMID:
9216088
43.

Dioleoylmelittin as a novel serum-insensitive reagent for efficient transfection of mammalian cells.

Legendre JY, Trzeciak A, Bohrmann B, Deuschle U, Kitas E, Supersaxo A.

Bioconjug Chem. 1997 Jan-Feb;8(1):57-63.

PMID:
9026036
44.

Large and small splice variants of collagen XII: differential expression and ligand binding.

Koch M, Bohrmann B, Matthison M, Hagios C, Trueb B, Chiquet M.

J Cell Biol. 1995 Aug;130(4):1005-14.

45.
46.

In situ localization of the 60 k protein of Helicobacter pylori, which belongs to the family of heat shock proteins, by immuno-electron microscopy.

Eschweiler B, Bohrmann B, Gerstenecker B, Schiltz E, Kist M.

Zentralbl Bakteriol. 1993 Sep;280(1-2):73-85.

PMID:
8280960
47.
48.

The inactive form of recA protein: the 'compact' structure.

Ruigrok RW, Bohrmann B, Hewat E, Engel A, Kellenberger E, DiCapua E.

EMBO J. 1993 Jan;12(1):9-16.

49.

Artefacts and morphological changes during chemical fixation.

Kellenberger E, Johansen R, Maeder M, Bohrmann B, Stauffer E, Villiger W.

J Microsc. 1992 Nov;168(Pt 2):181-201.

PMID:
1464902
50.

Coralline shape of the bacterial nucleoid after cryofixation.

Bohrmann B, Villiger W, Johansen R, Kellenberger E.

J Bacteriol. 1991 May;173(10):3149-58.

Supplemental Content

Loading ...
Support Center